551 related articles for article (PubMed ID: 19393842)
41. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Majmudar PA; Clinch TE
Cornea; 2014 May; 33(5):457-62. PubMed ID: 24637269
[TBL] [Abstract][Full Text] [Related]
42. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
Lopez Sisniega J; Profant M; Kostrica R; Waskin H
Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
[TBL] [Abstract][Full Text] [Related]
44. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections.
Nguyen AT; Hong AR; Baqai J; Lubniewski AJ; Huang AJ
Cornea; 2015 Aug; 34(8):967-71. PubMed ID: 26075451
[TBL] [Abstract][Full Text] [Related]
45. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
46. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Norcross EW; Sanders ME; Moore Q; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309
[TBL] [Abstract][Full Text] [Related]
47. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J; Kim A; Pratzer KA; Stark WJ
J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
[TBL] [Abstract][Full Text] [Related]
48. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
49. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
51. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
52. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
54. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Donnenfeld ED; Comstock TL; Proksch JW
J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
[TBL] [Abstract][Full Text] [Related]
55. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis.
Jauch A; Fsadni M; Gamba G
Graefes Arch Clin Exp Ophthalmol; 1999 Sep; 237(9):705-13. PubMed ID: 10447643
[TBL] [Abstract][Full Text] [Related]
56. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
57. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
Colin J; Paquette B
Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464
[TBL] [Abstract][Full Text] [Related]
59. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
